Biotechnology company Revance Therapuetics, Inc. purportedly concealed it might be breaching a long-term dermal-filler contract, imperiling a merger offer and sending the stock down over 20%, a proposed class action says.
Revance, which develops anti-wrinkle and pain-disorder injections, and two top executives misled investors and caused the stock-buy agreement to shrink to half its price, shareholder Cassandra Matney said in a complaint filed in the US District Court for the Middle District of Tennessee on Jan. 3.
In August 2024, Revance and Crown Laboratories, Inc., announced a agreement under which the privately-held skincare company would pay cash for outstanding Revance ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.